Related Experiment Video
Updated: Jun 12, 2026
06:04
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
Published on: March 6, 2018
[Benign prostatic hyperplasia: treatment options in the dog]
Schweizer Archiv Fur Tierheilkunde
|June 10, 2010
Summary
Benign prostatic hyperplasia (BPH) is common in older male dogs, causing prostate enlargement. Treatment options include surgery, hormonal therapy, or anti-androgens to manage symptoms effectively.
Area of Science:
- Veterinary Medicine
- Canine Urology
- Endocrinology
Context:
- Benign prostatic hyperplasia (BPH) is a common condition in aged intact male dogs.
- It involves non-inflammatory prostate enlargement due to epithelial and mesenchymal proliferation.
- Clinical symptoms like urethral discharge and hematuria occur in a minority of affected dogs.
Purpose:
- To outline the pathophysiology and clinical presentation of canine BPH.
- To review current therapeutic strategies for managing BPH in dogs.
- To emphasize the availability of diverse treatment options for clinicians.
Summary:
- BPH is characterized by prostate enlargement in over 95% of aged intact male dogs.
- While common, overt clinical signs are less frequent.
- Available treatments include surgical castration, GnRH-depot-analogues for hormonal suppression, 5alpha-reductase inhibitors, and anti-androgens.
Impact:
- Provides a comprehensive overview of canine BPH for veterinary professionals.
- Highlights the importance of considering various therapeutic approaches tailored to individual patients.
- Facilitates informed decision-making in managing this prevalent condition in dogs.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:30Urinary Tract Calculi III: Medical Management
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...